# Sirolimus for Leigh Syndrome

> **NCT06843811** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Matthew Demczko** · enrollment: 15 (estimated)

## Conditions studied

- Leigh Syndrome

## Interventions

- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT06843811
- **Lead sponsor:** Matthew Demczko
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-02-27
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06843811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06843811, "Sirolimus for Leigh Syndrome". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06843811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*